NASDAQ:CRBPCorbus Pharmaceuticals Stock Price, Forecast & News

Corbus Pharmaceuticals' stock was trading at $4.12 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CRBP shares have increased by 95.6% and is now trading at $8.06. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Corbus Pharmaceuticals.

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Corbus Pharmaceuticals.

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) issued its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.03. The biopharmaceutical company earned $1.76 million during the quarter, compared to analysts' expectations of $1.64 million. Corbus Pharmaceuticals had a negative return on equity of 282.91% and a negative net margin of 207.87%. View Corbus Pharmaceuticals' earnings history.

5 Wall Street analysts have issued 1 year price objectives for Corbus Pharmaceuticals' stock. Their forecasts range from $12.00 to $112.00. On average, they expect Corbus Pharmaceuticals' stock price to reach $39.80 in the next year. This suggests a possible upside of 393.8% from the stock's current price. View analysts' price targets for Corbus Pharmaceuticals.

Headlines about CRBP stock have trended very positive on Monday, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Corbus Pharmaceuticals earned a coverage optimism score of 4.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutCorbus Pharmaceuticals.

Some companies that are related to Corbus Pharmaceuticals include Ra Pharmaceuticals (RARX), Karuna Therapeutics (KRTX), Principia Biopharma (PRNB), Prestige Consumer Healthcare (PBH), Turning Point Therapeutics (TPTX), SAGE Therapeutics (SAGE), Madrigal Pharmaceuticals (MDGL), Ironwood Pharmaceuticals (IRWD), Pacira Biosciences (PCRX), Epizyme (EPZM), Aurinia Pharmaceuticals (AUPH), Corcept Therapeutics (CORT), Xencor (XNCR), IGM Biosciences (IGMS) and Ligand Pharmaceuticals (LGND). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Exelixis (EXEL), Viveve Medical (VIVE), Canopy Growth (CGC), Western Digital (WDC), Cronos Group (CRON) and Zynerba Pharmaceuticals (ZYNE).

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Corbus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.96%), ETF Managers Group LLC (4.92%), Pinnacle Associates Ltd. (1.69%), State Street Corp (1.60%), Geode Capital Management LLC (1.37%) and Morgan Stanley (1.07%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Craig Stuart Millian, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen. View institutional ownership trends for Corbus Pharmaceuticals.

CRBP stock was sold by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, AdvisorShares Investments LLC, UBS Group AG, Raymond James & Associates, Morgan Stanley, AE Wealth Management LLC, and Virtus ETF Advisers LLC. View insider buying and selling activity for Corbus Pharmaceuticals.

CRBP stock was bought by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Carmignac Gestion, DAFNA Capital Management LLC, BlackRock Inc., Geode Capital Management LLC, General American Investors Co. Inc., Alpine Global Management LLC, and Nuveen Asset Management LLC. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, Craig Stuart Millian, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran, and Yuval Cohen. View insider buying and selling activity for Corbus Pharmaceuticals.

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRBP stock can currently be purchased for approximately $8.06.

Corbus Pharmaceuticals has a market capitalization of $584.27 million and generates $36.14 million in revenue each year. The biopharmaceutical company earns $-71,450,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Corbus Pharmaceuticals employs 141 workers across the globe.

The official website for Corbus Pharmaceuticals is www.corbuspharma.com.

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]